Tweets
Studies on Psoriatic Arthritis Prevention
PsA is a sequelae to chronic skin psoriasis. Whether cutaneous psoriasis is the pre-clinical phase of what may become PsA is oft debated and has been inadequately researched.
https://t.co/5ESROnS6xk https://t.co/8Yte7JESZf
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Sequential Belimumab and RTX in SLE
Could disease control in active SLE patients be improved by the sequential use of subcutaneous BEL and intravenous RTX? A double blind trial has shown that sequential BEL and RTX was not superior to BEL alone in SLE.
https://t.co/CO0ltRX9Eo https://t.co/zey2UE4BRu
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Retrospective study of 919 RTX-treated GPA pts shows TMP-SMX prophylaxis (given to 31%) assoc w/ reduced serious infections (adj HR 0.5) and less outpatient infections (aHR 0.8). All 13 pneumocystis infx (PJP) occured in those not Rx w/ TMP-SMX. https://t.co/bO6oAHv7Lr https://t.co/fPntW75hnY
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Cohort of 112 VEXAS pts: skin involvement common (83%), esp early w/ LCV (36%), neutrophilic (34%) or perivascular dermatitis (30%). p.Met41Leu variant w/ PMN (Sweets?) dermatitis (82%); p.Met41Val variant w/ vasculitic lesions (55%). 92% respond to pred https://t.co/2ACXCGRsi5 https://t.co/tYqA26AlaF
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome - genetic disease with estimated prevalence of 1 in 4269 in men >50 year: systemic inflammation, progressive bone marrow failure, and inflammatory cutaneous manifestations https://t.co/hSmE64xzcU https://t.co/gWh4rvaaS3
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Gluten can be "a wicked antigen". Full read Review of the potential role of gluten in inflammation and autoimmunity. Undigested gluten peptides can be modified by luminal transglutaminase or delivered to gut mucosal immune cells https://t.co/eonHfpZZiN https://t.co/iKwbzg2Lbu
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
AR882, a URAT1 inhibitor, was given FDA Fast Track designation for potential treatment of clinically visible tophi in patients with gout. In the US 13 mill have gout & 2 mill have visible tophi. AR882 was presented at EULAR24 https://t.co/StvD3iz9AD https://t.co/G9SzxJysSD https://t.co/KcUSPVb5pn
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
2024 Update of EULAR recommendations for the Treatment of Systemic Sclerosis
https://t.co/52XEfgVCzZ https://t.co/d1zgTYUeOo
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
A Family History of Arthritis?
Using data from the population based All of Us Research Program, a self reported history of arthritis and related conditions was associated with an increased risk for arthritis, osteoporosis, and carpal tunnel syndrome.
https://t.co/SApbPLHquQ https://t.co/hOamnYyRoz
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Lipids and Inflammation in Rheumatoid Arthritis
In the realm of chronic inflammation, lipid abnormalities are well-recognized as pivotal contributors to the progression and clinical manifestations of atherosclerosis. Particularly in rheumatoid arthritis (RA), a systemic… https://t.co/zHKbBHlap8 https://t.co/KRIg1KYmcC
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Longitudinal US RA Registry of 31129 #RA pts (148K Pt-Yrs F/U) shows Higher RA Dz activity assoc w/ eGFR decline & renal dysfunction. Compared to remission, pts in Hi Dz activity had HR 1.27 risk for CKD G3a (<60cc) & HR 1.93 for CKD 3b (<45cc/min) https://t.co/UaFINRzqoM https://t.co/XXQviVO6jU
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Tyk2 inhibitor/Zasocitinib (TAK-279) effective in Psoriasis. Ph II RDBPCT of 259 pts w/ mod- severe plaque PsO showed 12 week PASI 75 success in 68% & 67% on 15 - 30 mg zasocitinib qd vs Placebo (18%). https://t.co/yyZwBYAP3H https://t.co/TvSSlEAKtR
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago


